Inovio DNA Vaccine Candidate INO-4800 for SARS-CoV-2
Inovio (INO) announced the publication of the preclinical study data for its novel coronavirus SARS-CoV-2 DNA vaccine INO-4800 which is demonstrating robust neutralizing antibody and T cell immune responses against COVID-19.
The study was published in the peer-reviewed journal Nature Communications titled, “Immunogenicity of a DNA vaccine candidate for COVID-19” by Inovio scientists and collaborators from The Wistar Institute, the University of Texas, Public Health England, Fudan University and others.
The promising results about the firm’s COVID-19 DNA vaccine INO-4800 emanated from preclinical testing. According to Dr. Kate Broderick, Inovio’s Senior Vice President of R&D and the Team Lead for COVID-19 vaccine development, these positive preclinical results not only highlight the potency of the firm’s DNA medicines platform but are supportive of the currently on-going INO-4800 clinical trials.